AGM Statement

RNS Number:3127K
Ardana PLC
11 October 2006



                                   Ardana plc

                            Annual General Meeting


Edinburgh, UK, 11 October 2006 - Ardana plc (LSE: ARA.L) confirms that all
resolutions put to the Annual General Meeting on 11 October 2006 were duly
passed.


Enquiries:



Ardana plc
[phone]
Dr Maureen Lindsay, Chief Executive Officer
Graham Lee, Chief Financial Officer



Financial Dynamics
[phone]
Julia Phillips
John Gilbert



About Ardana

Ardana plc is a pharmaceutical company focused on the discovery, development and
marketing of innovative products to improve human reproductive health, a $25.5
billion market.



Since its foundation, Ardana has maintained a broad and balanced portfolio to
manage risk and actively pursues product and technology in-licensing and
out-licensing to maintain a robust pipeline.



Ardana's lead products are summarised below:



  * Emselex(R), a treatment for overactive bladder for which Ardana has sole
    and exclusive promotion rights in the UK and will be launched in
    collaboration with Novartis Pharmaceuticals UK Limited;
  * StriantSR, a testosterone replacement therapy for which Ardana has
    marketing rights in Europe, has been launched by Ardana through its own
    sales force in the UK and partners in various European countries, as a
    treatment for men with confirmed hypogonadism;
  * Teverelix LA, in development for three initial indications: prostate
    cancer and benign prostatic hyperplasia (both indications are at the phase
    II stage), and endometriosis (currently in phase I);
  * Testosterone Cream, a transdermal testosterone delivery system in phase II
    for the treatment of male hypogonadism;
  * Invicorp(R), an injectable combination drug treatment for erectile
    dysfunction, already approved in Denmark and for which Ardana has marketing
    and manufacturing rights in Europe. Launch is expected in H2 2006;



In addition, Ardana has a strong portfolio of follow-on products in development.




For further information please see www.ardana.co.uk




                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

AGMFFFFDFSMSELS